Abstract | OBJECTIVES: Short-term treatment with a proton pump inhibitor (PPI) is effective for healing reflux esophagitis and improving reflux symptoms in pediatric patients. Our aim was to assess the efficacy and tolerability of maintenance PPI treatment after healing of reflux esophagitis in pediatric patients. MATERIALS AND METHODS: Systematic searches of MEDLINE, Excerpta Medica database, and recent conference abstracts. RESULTS: Five studies evaluated the efficacy of PPI maintenance therapy (6- to 90-month follow-up) in pediatric patients after healing of reflux esophagitis. Three found no relapse of reflux esophagitis or reflux symptoms during PPI maintenance therapy; however, a low relapse rate (1/14) was also found in the placebo group of the only prospective controlled study. Two of the 5 studies (both prospective) reported relapse of reflux esophagitis at half the original healing dose of omeprazole (7 of 51 patients relapsed after 3 months; 8 of 32 within 21 months), which resolved again in most patients when the healing dose or higher was given. Four studies evaluated relapse of reflux esophagitis and/or reflux symptoms after stopping PPI therapy. Reflux symptoms recurred in 18% to 76% of patients across all 4 studies. In the 4 studies that assessed the safety of PPI maintenance therapy, adverse events were infrequent and of low severity. CONCLUSIONS:
|
Authors | Marta Illueca, Börje Wernersson, Catherine Henderson, Per Lundborg |
Journal | Journal of pediatric gastroenterology and nutrition
(J Pediatr Gastroenterol Nutr)
Vol. 51
Issue 6
Pg. 733-40
(Dec 2010)
ISSN: 1536-4801 [Electronic] United States |
PMID | 20808247
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Omeprazole
|
Topics |
- Anti-Ulcer Agents
(therapeutic use)
- Child
- Esophagitis
(drug therapy, etiology)
- Gastroesophageal Reflux
(complications, drug therapy)
- Humans
- Omeprazole
(therapeutic use)
- Outcome Assessment, Health Care
- Proton Pump Inhibitors
(therapeutic use)
- Secondary Prevention
|